‘Gemini Therapeutics Merger Company Disc Medicine Granted FDA Orphan Designation For Erythropoietic Protoporphyria Treatment’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=916222
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Gemini Therapeutics And Disc Medicine Announce Merger Agreement
Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs
Combined company is expected to have approximately $175 million of
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
10 Biggest Price Target Changes For Friday
Needham cut the price target on OppFi Inc. (NYSE: OPFI) from $10 to $4.5. OppFi shares rose 5.3% to $3.20 in pre-market trading.
HC Wainwright & Co. Downgrades Gemini Therapeutics to Neutral, Lowers Price Target to $2
HC Wainwright & Co. analyst Andrew Fein downgrades Gemini Therapeutics (NASDAQ:GMTX) from Buy to Neutral and lowers the price target from $5 to $2.
What 5 Analyst Ratings Have To Say About Gemini Therapeutics
Within the last quarter, Gemini Therapeutics (NASDAQ:GMTX) has observed the following analyst ratings:
10 Biggest Price Target Changes For Thursday
Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.